Table 1.
Characteristics of v-safe respondents with reports related to menstruation or vaginal bleeding compared with total female v-safe respondents
| Respondents reporting menstrual irregularities or vaginal bleeding (n=63 815) | Total female v-safe respondents aged ≥18 years*(n=5 975 363) | ||
|---|---|---|---|
| Sex | |||
| Female | 62 679 (98·2%) | 5 975 363 (100·0%) | |
| Male† | 368 (0·6%) | .. | |
| Other | 206 (0·3%) | .. | |
| Unknown | 562 (0·9%) | .. | |
| Age group | |||
| 18–49 years | 57 997 (90·9%) | 3 095 361 (51·8%) | |
| 50–64 years | 5307 (8·3%) | 1 698 520 (28·4%) | |
| 65–74 years | 422 (0·7%) | 887 481 (14·9%) | |
| 75–84 years | 82 (0·1%) | 249 567 (4·2%) | |
| 85+ years | 7 (<0·1%) | 44 434 (0·7%) | |
| Race | |||
| White | 49 795 (78·0%) | 4 078 154 (68·2%) | |
| Black | 4866 (7·6%) | 442 955 (7·4%) | |
| Asian | 4929 (7·7%) | 412 249 (6·9%) | |
| American Indian or Alaska Native | 1230 (1·9%) | 67 631 (1·1%) | |
| Native Hawaiian or other Pacific Islander | 440 (0·7%) | 32 988 (0·6%) | |
| Other | 2948 (4·6%) | 218 213 (3·7%) | |
| Missing | 2685 (4·2%) | 849 895 (14·2%) | |
| Ethnicity | |||
| Hispanic or Latino | 8116 (12·7%) | 619 917 (10·3%) | |
| Not Hispanic or Latino | 52 850 (82·8%) | 4 421 916 (74·0%) | |
| Missing | 2851 (4·5%) | 933 538 (15·6%) | |
| Vaccine received‡ | |||
| BNT162b2 | 33 149 (51·9%) | 2 975 438 (49·8%) | |
| mRNA-1273 | 26 741 (41·9%) | 2 794 014 (46·8%) | |
| Ad26.COV2.S | 4072 (6·4%) | 285 775 (4·8%) | |
| Other/unknown | 3 (<0·1%) | 1662 (<0·1%) | |
| Reported dose§ | |||
| 1 | 54 180 (84·9%) | 4 935 274 (82·6%) | |
| 2 | 55 428 (86·9%) | 4 221 380 (70·6%) | |
| ≥3 | 11 366 (17·8%) | 745 158 (12·5%) | |
| Submitted survey§ | |||
| Dose 1 | |||
| 0–7 days | 51 828 (81·2%) | 4 725 436 (79·1%) | |
| 14 days | 46 934 (73·5%) | 3 766 825 (63·0%) | |
| 21 days | 28 079 (44·0%) | 2 292 256 (38·4%) | |
| 28 days | 8222 (12·9%) | 607 862 (10·2%) | |
| 35 days | 4594 (7·2%) | 216 797 (3·6%) | |
| 42 days | 4435 (6·9%) | 174 458 (2·9%) | |
| 3 months | 3994 (6·3%) | 358 875 (6·0%) | |
| 6 months | 3575 (5·6%) | 468 299 (7·8%) | |
| 12 months | 321 (0·5%) | 57 155 (1·0%) | |
| Dose 2 | |||
| 0–7 days | 52 752 (82·7%) | 3 920 283 (65·6%) | |
| 14 days | 46 192 (72·4%) | 3 262 994 (54·6%) | |
| 21 days | 44 570 (69·8%) | 3 113 097 (52·1%) | |
| 28 days | 42 958 (67·3%) | 2 982 212 (49·9%) | |
| 35 days | 42 625 (66·8%) | 2 913 033 (48·8%) | |
| 42 days | 41 545 (65·1%) | 2 864 136 (47·9%) | |
| 3 months | 41 537 (65·1%) | 2 827 283 (47·3%) | |
| 6 months | 38 616 (60·5%) | 2 783 393 (46·6%) | |
| 12 months | 469 (0·7%) | 50 053 (0·8%) | |
Data are n (%).
Includes respondents who did and did not report menstrual irregularities or vaginal bleeding.
Includes 192 individuals with responses that were unrelated or not definitively related to menstruation (eg, “I suffer from cluster headache and I am in the middle of a cycle”), ten individuals reporting symptoms experienced by someone else, and four individuals who specifically mention being transgender in the response.
150 respondents with responses related to menstruation or vaginal bleeding and 81 465 female v-safe respondents received vaccine doses from more than one manufacturer.
Includes v-safe entries that do not mention menstruation, vaginal bleeding, or other free-text symptoms.